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INTRODUCTION
Tissue regeneration is achieved through the coordinated regulation of tissue destruction via removal of damaged cells, tissue repair via the release of pro-regenerative signals (often pro-inflammatory cytokines), and production of replacement cells by activated tissue-specific stem cells (Naik et al., 2018) . Hematopoietic stem cells (HSCs) produce all mature blood cells and regenerate the blood system throughout life (Orkin and Zon, 2008) . The vast majority of adult HSCs are kept quiescent in the bone marrow (BM) and survive environmental stresses that kill most progenitor and mature cells (Mohrin et al., 2010; Warr et al., 2013) , thereby remaining able to initiate blood regeneration. HSCs respond to a wide range of insults by activating their metabolism and cell-cycle machinery, mobilizing into the circulation, and changing their differentiation output to increase the production of specific blood lineages (Baldridge et al., 2010; Essers et al., 2009; Pietras et al., 2016) . While all these mechanisms allow for HSC maintenance and rapid recovery of blood homeostasis after injury, how they are triggered and integrated to mediate an effective regenerative response remains elusive.
The tumor necrosis factor a (TNF-a) is one of the most intensively studied pro-inflammatory cytokines with central roles in mammalian immunity and cellular homeostasis (Silke and Hartland, 2013) . TNF-a is a prototypical death ligand induced upon infection that can elicit two types of programmed cell death, apoptosis and necroptosis (Brenner et al., 2015) . The fate of a TNF-a-exposed cell depends on the cellular context, particularly the ubiquitylation status of the receptor-interacting serine-threonine kinase 1 (RIPK1) enzyme, which is in large part regulated by the inhibitor of apoptosis protein (cIAP) E3 ubiquitin ligases. Upon TNF-a binding to its receptors (TNF-R), poly-ubiquitylated RIPK1 acts as a scaffold protein necessary for activating pro-survival signaling, essentially the canonical nuclear factor kB (NF-kB) pathway. In situations where RIPK1 remains nonubiquitylated, such as upon cIAP depletion, RIPK1 assembles with initiator caspases (CASPs) including CASP-8, whose activation leads to the execution of classical CASP-3/7-mediated apoptosis. In contrast, in cells where CASPs are inactivated, RIPK1 phosphorylates RIPK3, which in turn phosphorylates the mixed-lineage kinase-domain-like (MLKL) protein, resulting in the execution of necroptosis (Brenner et al., 2015) .
Despite such a detailed molecular understanding of TNF-a mechanisms of action, its role in HSC regulation remains controversial. Earlier studies report conflicting results for the effect of TNF-a on growth and proliferation of human hematopoietic progenitor in vitro, ranging from potent inhibition (Broxmeyer et al., 1986) to actual stimulation (Caux et al., 1990) . Similarly, studies using TNF-R knockout mice show opposite effects as to whether TNF-a acts in a positive (Pearl-Yafe et al., 2010) or negative (Pronk et al., 2011) manner on the survival of HSC-enriched populations. The impact of TNF-a on HSC engraftment potential is also highly debated, since both promoting and inhibitory effects are observed, depending on the experimental setting (Ishida et al., 2017; Pronk et al., 2011) . In addition, TNF-a, like other classical inflammatory signals, has emerged as an essential regulator of HSC ontogeny during embryonic development (Espin-Palazon et al., 2018) . RIPK1 has also been suggested to be critical for protection of hematopoietic cells from TNF-a-driven necroptosis (Roderick et al., 2014) , yet the ability of TNF-a to induce necroptosis in the most primitive HSCs and the importance of TNF-a-driven necroptosis in regulating HSC viability and function remain largely unaddressed. Here, we set out to clarify the effect of TNF-a on adult (legend continued on next page) HSC function and understand how TNF-a-dependent mechanisms are integrated to coordinate hematopoietic regeneration during inflammation.
RESULTS

Differential TNF-a Cytotoxicity on HSCs and Committed Progenitors
To assess the effect of TNF-a on hematopoiesis, wild-type (WT) mice were injected with various concentrations of TNF-a (0.5-4 mg per injection) using a previously published 48-h delivery protocol with three injections, 12 h apart, followed by a 24-h wait period ( Figure 1A) , which at the dose of 2 mg TNF-a reduced BM cellularity and compromised HSC engraftment potential (Pronk et al., 2011) . In fact, TNF-a treatment induced a dosedependent reduction in BM cellularity, which was already evident at 0.5 mg TNF-a ( Figure 1B ). Flow cytometry analyses ( Figure S1A ) also indicated a dose-dependent elimination of BM mature B cells and granulocytes (Gr) (Figures 1C and S1B), and their committed progenitors including common lymphoid progenitors (CLP), common myeloid progenitors (CMP), granulocyte-macrophage progenitors (GMPs) and megakaryocyteerythrocyte progenitors (MEPs) (Figures 1D and S1C-S1E). In contrast, the changes in the HSC-containing LSK (Lin À c-Kit + Sca-1 + ) compartment, which consists mainly of distinct populations of lineage-biased multipotent progenitors (MPPs) (Pietras et al., 2015) , were more contrasted. While lymphoid-primed MPP4 also showed a dose-dependent elimination, despite an initial increase at 0.5 mg TNF-a, myeloid-primed MPP2-3 displayed a sustained expansion and HSCs maintained rather constant numbers up to the highest dose of 4 mg TNF-a ( Figures  1E, 1F , S1F, and S1G). These results highlight the potent cytotoxic effect on TNF-a on nearly all BM hematopoietic populations, except for the most immature HSCs and MPP2-3. To further investigate the differential effect of TNF-a on HSCs and their progeny, we isolated HSCs and GMPs from WT mouse BM and performed in vitro cultures with or without (±) TNF-a (Figure 1G) . When expanded for 72 h (3 days) in cytokine-rich media, HSCs were not inhibited by TNF-a regardless of its concentration (1 ng to 10 mg/mL), whereas GMPs exhibited a consistent $50% reduction in cell number with as low as 10 ng/mL TNF-a ( Figure 1H ). Consistently, HSCs did not activate CASP-3/7 upon 24-h exposure with 1 mg/mL TNF-a, while GMPs strongly did ( Figure 1I ). Cultured MPP2-3 cells were also resistant to TNF-a cytotoxicity, while MPP4, CMPs, and MEPs were all susceptible ( Figure S1H ). Of note, the growth of HSC-containing LSK cells was reportedly suppressed by TNF-a when cultured with only stem cell (SCF) and granulocyte-colony stimulating (G-CSF) factors (Pronk et al., 2011) . However, the expansion rate and colony-forming ability of both HSCs and GMPs was already compromised in these ''cytokine-poor'' conditions (Figures 1J , S1I, and S1J), suggesting a possible confounding effect of other stress-response mechanisms activated by cytokine deprivation. In fact, we directly demonstrated induction of autophagy in cytokine-poor conditions using HSCs isolated from autophagy reporter GFP-LC3 mice (Mizushima et al., 2004; Warr et al., 2013) and showed a strong inhibition of this protective response upon TNF-a treatment ( Figure 1K ). Autophagy inhibition by TNF-a in these cytokine-poor culture conditions may therefore sensitize HSCs to cell death. Collectively, these results demonstrate that HSCs are highly resistant to TNF-a cytotoxicity, although their survival can be affected by other environmental stresses, whereas GMPs are eliminated by TNF-a in a dose-dependent manner by apoptosis. They also show that the resistance to TNF-a extends to myeloid-biased MPP2-3 but disappears shortly afterward, resulting in a broad hematopoietic clearance initiated at the MPP4 level in the LSK compartment.
TNF-a Drives Myeloid Regeneration from HSCs
We next investigated the kinetics of TNF-a response and associated hematopoietic regeneration using the same delivery protocol (three injections, 12 h apart) and 2 mg TNF-a ( Figure 2A ). We confirmed significantly increased TNF-a levels in the BM fluid of 24-h-injected mice, which rapidly became undetectable at 48 h ( Figure S2A ). Interestingly, BM HSC numbers transiently increased at 24 h, returned to basal levels at 48 h, and remained stable thereafter. In contrast, BM GMPs and Grs were depleted as early as 3 h after the first TNF-a injection, with GMP numbers fully recovering by 96 h. For Grs, we observed a transient overshoot by 96-144 h, indicative of ongoing myeloid regeneration and GMP cluster formation (Hé rault et al., 2017) , before normalizing by 192 h. To address the possibility of an egress of GMPs and Grs from the BM in response to TNF-a injections, we tracked their numbers in the spleen (SP) and peripheral blood (PB) (Figure 2B) . These kinetics analyses confirmed that HSCs expanded mainly in the BM at 24 h, with a small number of HSCs migrating and accumulating in the SP by 96 h. Interestingly, the rapid depletion of BM GMPs was not accompanied by a complementary increase in the periphery until the appearance of splenic GMPs by 96 h, likely as a consequence of in situ differentiation of homed HSCs ( Figure 2B ). Indeed, BM HSCs did not engage apoptosis at any time points, whereas BM GMPs showed massively increased CASP-3/7 activity at 3 h and 24 h (Figure 2C) , thus confirming their direct elimination by apoptosis. In contrast, we observed a transient increase in PB Grs at 3 h that could be explained by the known egress of TNF-a-exposed Grs into the circulation (Sadik et al., 2011) , although we cannot (I) CASP-3/7 activity in BM HSCs and GMPs after 24 h culture ± TNF-a (n = 14 pools of 200 cells per group from four independent experiments). Results are expressed as fold changes compared to untreated HSCs (set to 1). (J) Plating efficiency in methylcellulose of BM HSCs and GMPs after 24 h culture in cytokine-rich or -poor media ± TNF-a (n = 9 pools of 100 cells per group from 3 independent experiments). Colonies are scored after 7 days. (K) Autophagy flux in BM GFP-LC3 HSCs after 8-h culture in cytokine-rich or -poor media ± TNF-a and bafilomycin A (BafA) (n = 3 biological replicates from three independent experiments). Results are calculated as percent changes of GFP-LC3 mean fluorescence intensity (MFI) between +BafA versus ÀBafA conditions per treatment; Àcyto, no cytokines. Data are presented as mean ± SEM; *p < 0.05, **p < 0.01, and ***p < 0.001. See also Figure S1 . (legend continued on next page) formally exclude a quick differentiation of some TNF-a-exposed GMPs producing Grs that were immediately released in the circulation. However, this increase in PB Grs disappeared by 24 h and two additional injections of TNF-a, indicating a mostly depleting effect of TNF-a on Grs. Collectively, these results demonstrate that TNF-a transiently expands HSCs while rapidly eliminating GMPs and Grs, which is followed by hematopoietic regeneration upon return to normal TNF-a levels.
To understand how TNF-a triggers regeneration, we first assessed the cell cycle of HSCs isolated from TNF-a-treated mice ( Figure 2D ). As expected, HSCs quickly exited quiescence and started cycling by 24 h, an effect that persisted for at least 96 h but was fully restored by 192 h. Concomitantly, HSCs transiently shifted to a metabolically activated CD34 + MPP1 fate (Cabezas-Wallscheid et al., 2014) and a CD41 + myeloid-primed state (Yamamoto et al., 2013) , which was quickly reverted by 96 h (Figures 2E and 2F ). Fluidigm qRT-PCR analyses of 3 h-and 48-h HSCs revealed a sustained inhibition of quiescence-enforcing mechanisms and activation of the cell cycle and metabolic machineries ( Figure S2B ; Table S1 ). They also confirmed the strong induction of the master myeloid regulator Spi1 (PU.1) in 3-h HSCs, which was subsequently attenuated by 48 h. Using PU.1-eYFP knockin mice, we confirmed elevated levels of PU.1 protein in TNF-a-treated HSCs, which quickly peaked by 24 h before slowly declining ( Figure 2G and S2C). We also observed accelerated differentiation into myeloid cells from cultured 24 h HSCs ( Figures 2H and S2D ), which directly demonstrates their myeloid-priming. In vitro, the exposure of HSCs to TNF-a also accelerated cell division ( Figure S2E ), increased PU.1 levels ( Figure S2F ), and promoted myeloid differentiation ( Figure S2G ), although the produced myeloid cells were directly killed by apoptosis due to the constant presence of TNF-a in the culture media, leading to blunted expansion over time (Figures S2H and S2I) . Together, these results demonstrate that TNF-a activates a strong regenerative program in HSCs, leading to cell cycle activation and myeloid priming likely through precocious PU.1 activation. However, such TNF-a-driven myeloid regeneration is futile when TNF-a is still present, demonstrating that a tapering of TNF-a release is critical for effective restoration of blood homeostasis.
TNF-a-Mediated NF-kB Activity Prevents HSC Necroptosis
To understand the mechanisms by which TNF-a preserves HSCs while killing GMPs, we focused on the canonical NF-kB pro-survival signaling pathway ( Figure S3A ). We confirmed that both HSCs and GMPs express the two TNF-a receptors, with GMPs having higher levels of TNF-R1 than HSCs ( Figure S3B ). Using NF-kB-eGFP reporter mice, we showed the immediate activation of NF-kB in TNF-a-exposed HSCs and GMPs, with stronger NF-kB activity observed in HSCs ( Figure 3A ). We also found higher expression and more robust nuclear translocation of p65 (RelA) and p50 (Nfkb1) in TNF-a-treated HSCs compared to GMPs (Figures 3B) . Importantly, treatment with the IkB kinase inhibitor (IKKi) BMS-345541 partially inhibited p65 nuclear translocation ( Figure S3C ), and rendered HSCs partly, and GMPs completely, susceptible to TNF-a cytotoxicity ( Figure 3C ). However, p50 deficiency in p50 À/À mice had no effect on HSC survival while further promoting GMP death by apoptosis (Figure 3C) . In contrast, p65 loss in Mx1-Cre:p65 f/f conditional knockout (p65 cKO ) mice completely abrogated HSC resistance to TNF-a cytotoxicity, with both p65 cKO HSCs and GMPs being killed by apoptosis ( Figures 3C and 3D) . Interestingly, the capacity of TNF-a to activate p65 was maintained in p50 À/À HSCs (Figure S3D ), which suggest that the transcriptional program responsible for HSC survival might be activated solely by p65, perhaps through p65 homodimers or other atypical heterodimers without p50. Collectively, these results indicate that HSCs entirely rely on strong p65-dependent NF-kB activity to survive TNF-a exposure.
To further characterize the cell death pathways that are blocked by the strong NF-kB induction in TNF-a-treated HSCs, we next isolated HSCs from various apoptosis-(i.e., Mx1-Cre: Casp8 f/f , Bid À/À , and Mx1-Cre:Bak À/À :Bax f/f ) and necroptosisdeficient (i.e., Ripk1 kinase-dead (Ripk1 KD ), Ripk3 À/À , and Mlkl À/À ) mice ( Figure S3A ) and submitted them to 72 h in vitro expansion assay ± TNF-a and IKKi to partially block TNFa-induced NF-kB activity. Surprisingly, while apoptosis inhibition did not rescue TNF-a cytotoxicity caused by partial NF-kB blockade, necroptosis inhibition fully restored HSC survival ( Figure 3E ). The importance of necroptosis in TNF-a-mediated HSC elimination was reinforced in p65 cKO HSCs with complete NF-kB blockade, since only concurrent inhibition of both apoptosis via treatment with the pan-CASP inhibitor (CASPi) zVAD-fmk, and necroptosis via Ripk3 deficiency in Mx1-Cre:p65 f/f :Ripk3 À/À mice could restore HSC survival (Figures  3F) . These results were recapitulated by treating p65 cKO HSCs with both zVAD-fmk and the RIPK1 kinase inhibitor (RIPK1i) GSK'963 (Berger et al., 2015) ( Figure S3E ). In contrast, the cytotoxic effects of TNF-a on GMPs could not be rescued by apoptosis or necroptosis inhibition or a combination of both ( Figures S3E-S3G ), suggesting the involvement of an additional form of programmed cell death when apoptosis is inhibited. Collectively, these results demonstrate that TNF-a-induced p65-NF-kB activity protects HSCs primarily from necroptosis, which is the first form of cell death unleashed upon decreased NF-kB activity ( Figure S3H ).
TNF-a-Mediated Pro-survival Gene Signature in HSCs
To gain a broader understanding of the mechanisms dictating differential survival outcomes following TNF-a exposure, we performed RNA sequencing (RNA-seq) analyses on both HSCs and GMPs exposed to TNF-a in culture for 3 h and 12 h or isolated from TNF-a-treated mice at 3 h ( Figure 4A ). We selected these conditions to extract common gene expression signatures, which are independent of the treatment conditions and reflect an early response when p65-NF-kB is differentially activated between the two population and necroptosis or apoptosis (legend continued on next page) not yet engaged. Principal-component analysis (PCA) confirmed that TNF-a-treated cells are transcriptionally distinct from untreated cells, with a greater number of significantly affected genes in HSCs compared to GMPs (Figures 4B and 4C; Table  S2 ). We also observed a larger effect upon in vivo treatment compared to in vitro exposure, likely reflecting the contribution of indirect environmental effects not observed upon direct TNF-a stimulation By using only genes that were upregulated in all three TNF-a treatment conditions, which had a false discovery rate (FDR) <0.1 and fold changes (FCs) >3, we extracted a stringent TNF-a signature of 62 genes in HSCs and 51 genes in GMPs ( Figures 4C and 4D ; Tables S3-S5). 18 of those genes were commonly upregulated in both cell types and represented core regulators of the NF-kB pathway (Table  S6 ). Strikingly, the remaining 33 GMP-specific genes highlighted a clear pro-death signature, with enrichment of gene ontology (GO) terms, including apoptosis and inflammation, and upregulation of genes such as Tnf (TNF-a) itself, Lta (lymphotoxin-a), and Il6 (interleukin-6 [IL-6]). In contrast, the remaining 44 HSCspecific genes defined a strong pro-survival signature, characterized by anti-inflammatory GO terms and anti-apoptotic genes, including Birc3 (cIAP2), which directly blocks the cytotoxic effect of TNF-a by ubiquitylating RIPK1 (Brenner et al., 2015; Wallach et al., 2016) , as well as Cd274 (PD-L1) and Pdcd1lg2 (PD-L2), which are ligands for the PD-1 receptor that induce immune tolerance (Okazaki et al., 2013) . Taken together, these molecular data provide two novel TNF-a gene signatures that reflect the actual pro-survival and pro-death effect of TNF-a on HSCs and GMPs, respectively. Next, we investigated the role of the uncovered signature genes in mediating HSC survival upon TNF-a exposure. We first confirmed that Birc3 was the only cIAP family members induced in a p65-dependent manner in TNF-a-treated HSCs ( Figure 4E ). We then used two synthetic second mitochondria-derived activator of CASP (SMAC) mimetics, the dimeric AEG40730 and monomeric LCL-161 compounds (Fulda and Vucic, 2012) , to rapidly trigger cIAP degradation in TNFa-treated HSCs. Remarkably, despite preserved p65 nuclear translocation ( Figure 4F ), cIAP inhibition (cIAPi) rendered HSCs highly sensitive to TNF-a cytotoxicity (Figures 4G) . We also confirmed the transcriptional upregulation, mainly via p65 activation, and the increased surface expression of PD-L1 and PD-L2 protein in TNF-a-treated HSCs (Figures 4H and 4I) . Moreover, we showed in co-culture experiments that TNF-a-treated HSCs could block the increased proliferation of BM CD8 + T cells induced by TNF-a exposure, which was reverted by treatment with an anti-PD-1 blocking antibody (Figure 4J) . Together, these results demonstrate the functional role of the TNF-a signature genes in protecting HSCs from necroptosis via cIAP2 induction and providing the immunomodulatory capacity to suppress T cell proliferation through upregulation of PD-L1 and PD-L2.
Rapid NF-kB Deactivation Renders Active HSCs Susceptible to Necroptosis
To directly assess the effect of TNF-a on HSC regenerative function in vivo, we transplanted HSCs isolated from TNF-a-treated WT mice at various times post-TNF-a injections ( Figure 5A ). As expected, the engraftment potential of TNF-a-treated HSCs matched their activation state, with 3-h HSCs, which had just started entering the cell cycle, having minimally decreased engraftment compared to PBS-treated (0-h) HSCs; 48-h HSCs, which had exited quiescence, having severely compromised reconstitution ability; and 192-h HSCs, which had restored quiescence, having normal engraftment and BM reconstitution potential ( Figures 5B and 5C ). However, no major changes in lineage distributions was observed from TNF-a-treated HSCs at any time points ( Figures S4A and S4B) . Remarkably, 48-h HSCs showed no nuclear p65 signal in contrast to 3 and 24-h HSCs ( Figures 5D and 5E ), which reflected a deactivation of the NF-kB pathway that was also observed at the molecular level with rapid downregulation of canonical NF-kB target genes and the pro-survival gene Birc3 in 48-h HSCs ( Figures S4C and S4D ). This transient NF-kB signaling response is likely a direct consequence of TNF-a levels having returned to baseline by 48 h (Figure S2A) . Interestingly, 48-h HSCs also showed impaired growth in the 72-h expansion assay, which could be recovered upon in vitro TNF-a supplementation and reactivation of the NF-kB pathway ( Figures S4E-S4G ). Moreover, injection of TNF-a to lethally irradiated WT recipients (three injections, 12 h apart, starting 12 h post-transplantation) significantly improved the engraftment ability of 48-h HSCs while having no effect on the reconstitution capability of 0-h HSCs (Figures S4H and S4I ). Collectively, these results demonstrate a transient impairment of the engraftment potential of TNF-a-treated HSCs, which correlates with both cell-cycle activation and status of the NF-kB pathway. They indicate that fully activated HSCs with deactivated NF-kB response have the lowest regeneration potential, which stress the importance of the strength and duration of TNF-a signaling in dictating HSC engraftment capability. They also show no sustained myeloid skewing for the output of TNF-a-exposed HSCs, presumably because of the transient nature of the myeloid priming that reverts within a few days upon loss of TNF-a signaling.
To further dissect the involvement of necroptosis, we performed kinetics analyses of TNF-a-treated necroptosis-deficient mice ( Figures 5F and S5A-S5C ). Interestingly, while HSC numbers consistently increased at 24 h and then contracted at 48 h in WT mice, they were either maintained or further increased at 48 h in Ripk3 À/À and Mlkl À/À mice. In contrast, GMP and Gr numbers were similarly depleted in Ripk3 À/À and Mlkl À/À mice at 24 h but were regenerated faster than in WT mice at 48 h. HSCs from necroptosis-deficient mice also showed similar cell-cycle activation compared to WT HSCs upon TNF-a exposure ( Figures S5D and S5E) . These results indicate that HSCs (legend continued on next page) undergo necroptosis during the 24-48-h time window post-TNFa injection, when NF-kB is deactivated, and that inhibition of necroptosis in Ripk3 À/À and Mlkl À/À mice results in increased numbers of activated HSCs that participate to a faster regeneration of myeloid lineage cells and recovery of BM cellularity (Figure S5F) . Moreover, the defective expansion potential of 48-h HSCs was fully rescued by inhibition of necroptosis in 48-h Ripk3 À/À and Mlkl À/À HSCs (Figures 5G and 5H) . The impaired engraftment potential of 48-h HSCs was also significantly improved by necroptosis inhibition (Figures 5I and 5J ), although this rescue was only partial likely because of the persisting cellcycle activation of 48-h Ripk3 À/À and Mlkl À/À HSCs at the time of transplantation ( Figures S5D and S5E) . Taken together, these results demonstrate that HSCs become susceptible to necroptosis-mediated cell killing during the particular phase following TNF-a exposure when they are actively proliferating but devoid of p65-NF-kB-mediated pro-survival signaling. Moreover, they identify two instances when necroptosis plays an active role in controlling the size of the HSC compartment in vivo.
TNF-a Protects HSCs from Necroptosis and Promotes Myeloid Priming during Inflammation
To address the importance of TNF-a during inflammation, we used a well-established model of chronic inflammation with repeated injections of polyinosinic:polycytidylic acid (pIC) mimicking an antiviral immune response (Essers et al., 2009; Pietras et al., 2014) ( Figure 6A ). Multiplex cytokine measurement confirmed TNF-a as one of the most increased cytokines in the BM fluid of WT mice treated with 10 mg/kg pIC for 13 days (seven injections, every other day, followed by a 24-h wait period) ( Figures 6B and  S6A ). We previously reported that endothelial cell-selective adhesion molecule (ESAM)-selected HSCs (HSC ESAM ) were free of contaminating progenitors and essentially preserved during pICinduced inflammation, while other progenitors, including GMPs, were depleted ( Figures 6C and S6B ) . In contrast, pIC-induced inflammation strongly depleted HSC ESAM in Tnf À/À mice, while the reduction in GMPs remained very similar between pIC-treated WT and Tnf À/À mice ( Figure S6C ). The lack of TNF-a signaling did not affect the cell-cycle activation of pICtreated HSC ESAM ( Figure S6D ), but it partially attenuated their myeloid priming, as demonstrated by the delayed myeloid differentiation from pIC-treated Tnf À/À HSC ESAM in vitro ( Figure 6D and S6E). Furthermore, we observed severely compromised NF-kB activation in response to pIC treatment in the absence of TNF-a, as shown by the lack of reporter activity in NF-kB-eGFP:Tnf À/À HSC ESAM ( Figure 6E ) and p65 nuclear localization in isolated Tnf À/À HSC ESAM (Figures 6F and 6G) . In fact, TNF-a appeared as the major source of NF-kB activation during inflammation, as removal of IL-1 signaling, another known NF-kB inducer secreted in response to pIC treatment ( Figure S6A ), did not compromise p65 nuclear translocation in pIC-treated Il1r1 À/À HSC ESAM (Figures 6F and 6G ). Furthermore, blockade of necroptosis in Tnf À/À :Ripk3 À/À or Tnf À/À :Mlkl À/À mice completely rescued the loss of HSC ESAM induced by pIC treatment in the absence of TNF-a ( Figures 6H and 6I) , demonstrating that HSCs are directly eliminated by necroptosis during inflammation when TNF-a-driven NF-kB signaling is abrogated. The lack of TNF-a signaling also attenuated the elimination by apoptosis of pICtreated GMPs (Figure S6F ), but the overall reduction of HSC number and their impaired myeloid priming likely masked this rescue effect on GMP survival due to a globally impaired regenerative response in pIC-treated Tnf À/À mice. Finally, we confirmed the importance of TNF-a for HSC maintenance in other inflammatory contexts, including 48-h lipopolysaccharides (LPS) challenge that elicits an anti-bacterial immune response ( Figures S7A) and repeated 5-fluorouracil (5-FU) injections that trigger damageassociated BM ablation ( Figure S7B ). In both cases, TNF-a deficiency in Tnf À/À mice resulted in a significant loss of HSC numbers, although it still remains to be determined whether TNF-a itself or other ligands induced by TNF-a act directly on HSCs to prevent their depletion. Taken together, these results highlight the importance of TNF-a in maintaining NF-kB activity during inflammation, which protects HSCs from necroptosis-mediated elimination and drives myeloid regeneration.
Hijacking of TNF-a-Mediated Mechanisms in Dysregulated Hematopoiesis TNF-a levels are constitutively elevated during aging and in hematological malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) . To understand how TNF-a could contribute to HSC dysregulation in these conditions, we used our pro-survival HSCspecific TNF-a signature genes (HTSGs) to perform gene set enrichment analyses (GSEAs) on both mouse and human RNAseq datasets. Analyses of young (8-to 12-week-old) and aged (22-month-old) mouse HSCs revealed a specific enrichment for HTSG in old HSCs ( Figure 7A ), consistent with the increased NF-kB activity reported in aged HSCs (Chambers et al., 2007) . Moreover, analyses of human AML (Gentles et al., 2010) and MDS (Woll et al., 2014) patient samples also showed a specific enrichment for HSTG in AML leukemic stem cells (LSCs) and MDS HSCs (M-HSCs), which was not observed in normal HSCs or with the GMP-specific TNF-a signature genes (GTSG) ( Figures 7A and 7B ). This is in line with the constitutive NF-kB activation reported in human AML patients (Guzman et al., 2001) and confirmed here in HSC-derived LSCs from a BCR-ABL-driven leukemia mouse model ( Figure S7C) . In contrast, we found a significant enrichment for GTSG in AML blasts (Figure 7B) , illustrating the fact that a high proportion of cells respond to TNF-a in AML patients (Stirewalt et al., 2008) . Taken together, (legend continued on next page) these results demonstrate that HTSG successfully detects TNFa response in aged and malignant stem cells.
DISCUSSION
Here, we provide a novel integrated picture of the role of TNF-a as a key pro-regenerative inflammatory cytokine in the local BM niche microenvironment ( Figure 7C ). We show that regardless of its concentration, TNF-a primarily provides pro-survival cues to HSCs while inducing apoptosis in a dose-dependent manner in committed progenitors and mature cells. These opposing effects on survival outcome are, in large part, attributable to differences in the strength of canonical NF-kB activation, with a dominant role for p65-mediated regulations in HSCs. In fact, we demonstrate that a strong TNF-a-driven p65-NF-kB signaling leading to robust cIAP2 expression is essential for protecting HSCs from engaging cell-death mechanisms, especially necroptosis. TNF-a also rapidly induces emergency myelopoiesis leading to HSC activation and PU.1-mediated myeloid priming, which together facilitate the rapid recovery of myeloid lineage cells and restoration of blood homeostasis upon normalization of TNF-a levels. However, during this period of reduced TNF-a signaling, HSCs become susceptible to necroptosis-mediated killing due to p65-cIAP2 pathway deactivation, which together with their cycling status contribute to a contraction of the HSC pool and a significant but transient loss of their engraftment potential. In addition, TNF-a endows HSCs with the capability of suppressing T cell response via the PD-1 pathway, which may protect HSCs from excessive immune activation, as demonstrated in other contexts (Zheng et al., 2011) . However, it remains to be established whether and how PD-L1 and PD-L2 upregulation protects HSCs from T-cell-mediated cytotoxicity following in vivo activation by TNF-a. Together, our results decipher the molecular mechanisms by which TNF-a regulates survival, cellular activation, myeloid commitment, and immune tolerance in HSCs while at the same time promoting cell death in most of their downstream progeny. Our findings establish several guiding principles that help explain much of the controversies surrounding the effect of TNF-a on HSC survival and function. First, the effect of TNF-a is highly cell-type dependent, with only HSCs and MPP2-3 being molecularly geared to survive TNF-a exposure. One issue with many previous studies, including the work we used as reference for our treatment conditions, is the utilization of poorly purified populations for in vitro expansion assay (usually LSK cells, which contain a large fraction of MPP4 cells that are highly susceptible to TNF-a cytotoxicity). Hence, the reported pro-death effect of TNF-a on HSC-containing LSK cells (Pronk et al., 2011) likely reflects the elimination of these susceptible and abundant cells. A similar explanation applies to methylcellulose cultures containing TNF-a (Ishida et al., 2017) , since the produced myeloid cells are likely killed by TNF-a, as we showed here for TNF-a-containing liquid cultures. Second, the effect of TNF-a is influenced by the cytokine milieu. In particular, HSCs can become susceptible to TNF-a cytotoxicity when cultured in limited cytokine conditions (Pronk et al., 2011) , which we reveal to be the indirect consequence of TNF-a-mediated blockade of a protective autophagy response induced by cytokine deprivation (Warr et al., 2013) . This demonstrate that careful attention must be paid to the cytokine milieu when testing for TNF-a responses in vitro and that rich cytokine conditions are better at mimicking in vivo conditions, including inflammation. Third, the effect of TNF-a is very transient, with the pro-survival p65-cIAP2 pathway being quickly deactivated in the absence of persistent TNF-a signaling. When this happens while HSCs are cycling, it creates a window of susceptibility to necroptosis killing that only disappears when HSCs reenter quiescence. We identify three different instances where necroptosis-mediated killing of HSC occurs in vivo: (1) following acute TNF-a induction to cull the number of activated HSCs, (2) upon transplantation of TNF-a-exposed HSCs to limit their engraftment potential, and (3) during chronic inflammation without TNF-a signaling to deplete the HSC pool. However, it is likely that elimination of HSCs via necroptosis is an underappreciated feature of many other conditions, including BM failure syndrome, as previously suggested in the RIPK1-deficient inflammatory context (Rickard et al., 2014; Roderick et al., 2014) . This susceptibility to necroptosis coupled with differences in cell-cycle status is also likely at the heart of the diversity of engraftment behavior reported in the literature for TNFa-exposed HSCs.
Our results highlight the importance of cIAP2 in preventing the engagement of cell death mechanisms in TNF-a-exposed HSCs. The half-life of cIAP2 can be as short as 3 h (Lee et al., 2015) , and we show quick decreases of Birc3 expression upon NF-kB deactivation in HSCs. Rapid cIAP depletion has been reported to trigger the formation of a pro-death complex, which can initiate necroptosis when CASP-8 activity is inhibited (Brenner et al., 2015) . Since only necroptosis, and not apoptosis, is induced upon NF-kB deactivation, it suggests the involvement of some endogenous CASP inhibitors that could still be activated by low-level p65 signaling. One such possibility is a short isoform of the cellular FLICE-like inhibitory protein (cFLIP), which is a known p65 target directly inhibiting CASP-8 activity (Brenner et al., 2015) and is induced in TNF-a-treated HSCs according to our RNA-seq analyses. This would be consistent with the engagement of apoptotic killing solely when NF-kB signaling is completely abrogated in p65-deficient TNF-a-treated HSCs. The observation that HSCs can also be killed by necroptosis in pIC-treated Tnf À/À mice indicates that necroptosis can be triggered independently of TNF-a, likely via other exogenous factors such as interferons (IFNs), Toll-like receptor ligands, or other death ligands. Given that IFN-a is induced in the serum of pICtreated mice and is one of the known necroptosis inducers (Wallach et al., 2016) , it suggests that TNF-a could protect HSCs from IFN-a-induced necroptosis during inflammation. Our results demonstrate that TNF-a coordinates hematopoietic regeneration and stimulates emergency myelopoiesis from HSCs via precocious activation of PU.1, as recently confirmed in an independently study (Etzrodt et al., 2019) and already observed for IL-1 . However, in contrast to the long-lasting effect of IL-1, which has a prominent reprograming effect recently confirmed at the epigenetic level and termed trained immunity (Naik et al., 2018) , TNF-a only shows a transient ability to poise HSCs for myeloid differentiation, which rapidly disappears upon interruption of TNF-a signaling. Nevertheless, TNF-a signaling, and not IL-1 signaling, appears the key driver of p65-NF-kB activation and enhanced myeloid differentiation during pIC-induced inflammation. In addition, TNF-a-mediated PU.1 upregulation could contribute to the reestablishment of HSC quiescence by inhibiting cell-cycle activators (Staber et al., 2013) , thus helping protect HSCs from necroptosis and ter- minating the regenerative response. The observation that TNF-a eliminates myeloid progenitors by apoptosis may also appear counterintuitive, as they are an important source of mature myeloid cells that act as a first line of defense (Sadik et al., 2011) . In fact, while TNF-a always stimulates myelopoiesis, it only kills GMPs in a dose-dependent manner. Moreover, while HSCs are known to be highly resistant to pathogen infection (Baldridge et al., 2010) , virally infected hematopoietic progenitors, including GMPs, can serve as a reservoir for viral latency in the BM and a mediator of viral dissemination to other organs (Kondo et al., 1994) . Since TNF-a signaling is designed to detect cells that are infected (Silke and Hartland, 2013) and TNF-a levels closely correlate with viral activity (Dö cke et al., 1994) , it is conceivable that such differential and dose-dependent TNF-a killing mechanism has been developed to eliminate infected progenitors while preserving HSCs to provide new replacement progenitors, hence preventing the establishment of latent infection. Our results are also compatible with the fact that some specialized immune cells such as macrophage or T cells, which are required for pathogen or damaged cell clearance, are activated and not killed by TNF-a. Therefore, the mechanism we describe here may act as a fail-safe mechanism to determine the level of cell killing according to the severity of the ongoing infection. It will now be interesting to test this possibility using an established infection model. In addition, to strictly dissect the direct versus indirect effect of TNF-a on HSCs during inflammation, one would need to develop a sophisticated system where only HSCs, and not the other stromal and hematopoietic cell types, are unable to respond to TNF-a.
Finally, while TNF-a and NF-kB gene signatures are the most ubiquitous inflammatory signatures in gene expression analysis software, they are also the vaguest in terms of functional significance, as they do not pinpoint to a particular cellular outcome. In this regard, our work identifies two novel TNF-a gene signatures representative of a TNF-a-mediated pro-survival response in HSCs and pro-death effect in GMPs, which could potentially prove critical for deciphering the pathogenesis of human leukemia and identifying new treatment strategies. Although the precise role of elevated TNF-a in aged organisms or patients with hematological disorder remains to be investigated, it is intriguing to speculate that by keeping MDS-HSCs alive, TNF-a might favor the progression of MDS to AML, and conversely, that blockade of TNF-a-mediated pro-survival effects through additional mutations might contribute to the development of BM failure syndromes (Ogawa, 2016) . Moreover, our results raise the possibility of unanticipated broad hematopoietic toxicity associated with the clinical use of TNF-a inhibitors for treating inflammatory diseases, as already suggested by anecdotal case reports showing the development of pancytopenia in patients receiving anti-TNF-a therapy for rheumatoid arthritis (Day, 2002) . Understanding how dysregulation of these TNF-a-dependent mechanisms contribute to the development of hematological disorders would help further develop therapeutic interventions targeting dysregulated HSCs while sparing normal HSCs.
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Emmanuelle Passegué , ep2828@cumc.columbia.edu. Mouse TNF-a was obtained from Genentech under an MTA. GSK'963 was obtained from GlaxoSmithKline under an MTA.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice CD45.2 C57BL/6J, CD45.1 C57BL/6-BoyJ (B6.SJL-Ptprc a Pepc b /BoyJ), p50 -/-(B6.Cg-Nfkb1 tm1Bal /J) and Il1r1 -/-(B6.129S7-Il1r1 tm1Imx /J) mice were purchased from the Jackson Laboratory and bred in our animal facility. Mlkl -/mice (Murphy et al., 2013) were obtained from Dr. A. Warren, Walter and Eliza Hall Institute of Medical Research, Australia. Ripk1 D138N/D138N (Ripk1 KD ) mice (Newton et al., 2014) were obtained from Dr. K. Newton, Genentech. Tnf -/- (Pasparakis et al., 1996) and Ripk3 -/mice (He et al., 2009) were obtained from Dr. A. Ma, UCSF. Casp8 f/f mice (Beisner et al., 2005) were obtained from Dr. S. M. Hedrick, UCSD. Bid -/mice (Yin et al., 1999) were obtained from Dr. S. Zinkel, Vanderbilt University. Bak -/-Bax f/f , GFP-LC3, PU.1-eYFP and Scl-tTA:TRE-BCR/ABL mice were described previously (Warr et al., 2013) . p65 f/f mice (Alg€ ul et al., 2007) were obtained from Dr. R. Schmid, Technical University of Munich, Germany. NF-kB-eGFP mice (Magness et al., 2004) were obtained from Dr. C. Jobin, University of North Carolina, and maintained as hemizygotes. Six-to 12-week-old mice were used as donor for cell isolation and in vivo experiments, and eight-to 12-week-old congenic mice were used as recipients for HSC transplantation experiments. Respective littermates or age-matched WT animals were used as controls. No specific randomization or blinding protocol was used, and both male and female animals were used indifferently in the study. For Mx1-Cre-mediated deletion, four-to 6-week-old Mx1-Crepositive or -negative mice were injected intraperitoneally once (p65 flox allele) or three times every other day (Casp8 and Bax flox alleles) with 250 mg of poly I:C (pIC, GE Healthcare, 27473201) in 200 ml PBS. pIC injection was completed at least 4 weeks prior to each experiment, and pIC-injected Mx1-Cre-negative mice were used as controls. All mice were maintained in mouse facilities at UCSF or Columbia University in accordance with IACUC approved protocols approved at each institution.
METHOD DETAILS
In vivo assays For in vivo TNF-a treatment, mice were injected retro-orbitally with 0.5 to 4 mg mouse TNF-a (Genentech) in 100 mL PBS or 100 mL PBS alone (untreated animals) up to 3 times every 12 hours. For pIC-induced inflammation experiments, mice were injected intraperitoneally with 10 mg/kg pIC in PBS or PBS alone every other day for 13 days (7 times). For LPS-induced inflammation experiments, mice were injected intraperitoneally with 2 mg/kg LPS (Sigma-Aldrich, L2880) in PBS (1 time). For repeated 5-fluorouracil (5-FU) treatment, mice were injected intraperitoneally with 150 mg/kg 5-FU (Sigma-Aldrich, F6627) in PBS every month for 3 months (3 times). For transplantation experiments, recipient mice were lethally irradiated (11 Gy, delivered in split doses 3 hours apart) using a 137 Cs source (J.L. Shepherd), and injected retro-orbitally with 500 donor HSCs together with 3x10 5 Sca-1-depleted BM cells within the next 36 hours following irradiation. For in vivo TNF-a supplementation after transplantation, recipient mice were injected retro-orbitally with 2 mg mouse TNF-a in 100 mL PBS or 100 mL PBS alone for 3 times 12 hours apart starting 12 hours after transplantation. Transplanted mice were maintained on antibiotic-containing water for 4 weeks, and analyzed for donor hematopoietic chimerism by Flt3-L (25 ng/ml), IL-11 (25 ng/ml), IL-3 (10 ng/ml), GM-CSF (10 ng/ml) and EPO (4 U/ml). For liquid culture with cytokine-poor media, only SCF (25 ng/ml) and G-CSF (25 ng/ml, PeproTech) were used. TNF-a (Genentech) was added at 1 mg/ml unless otherwise indicated. For 3-day expansion assays, 300-500 cells were directly sorted per well of a 96-well plates in 200 mL of culture media, then TNF-a and the other drugs and/or cytokines were added, and cells were manually counted after 3 days using a hemocytometer and trypan blue exclusion of dead cells. BMS-345541 (2 mM, Sigma-Aldrich, B9935), LCL-161 (5 mM, ChemiTek, CT-LCL161) and AEG40730 (4.5 mM, Tocris, 5330) were added at the same time than TNF-a, while GSK'963 (10 mM, GSK) and zVAD-fmk (20 mM, Bachem, N-1510) were added 1 hour before the addition of TNF-a. Bafilomycin A (Sigma-Aldrich, B1793) was used at 5 nM. For clonogenic methylcellulose colony assays, 100 HSCs or 250 GMPs were cultured for 24 hours with or without TNF-a in liquid media, and then transferred into a 35-mm dish containing 1 mL methylcellulose (StemCell Technologies, M3231) supplemented with L-glutamine, penicillin/streptomycin and cytokines described above. Colonies were manually counted under a microscope after 7 days of culture. For apoptosis assays, 200 cells were seeded per well of a 384-well white luminescence plate in 40 mL of liquid media and 40 mL of Caspase-Glo 3/7 reagent (Promega, G8091) were added to each well. Plates were then shaken at 300 rpm for 1 min, incubated for 60 min at room temperature and read on a luminometer (Synergy2, BioTek or Victor 3V, Perkin Elmer). Background luminescence was determined with 40 mL of culture media without cells and subtracted before calculation of fold changes. For myeloid differentiation and surface marker tracking, 1,000-2,000 HSCs were directly sorted per well of a 96-well plates and cultured for up to 8 days. Cytokines were refreshed every other day by replacing $30% of the total volume with fresh media, and cells were analyzed by flow cytometry after different culture periods. For CFSE dilution assay, sorted BM CD8 + T cells were labeled with 2.5 mM CFSE (Molecular Probes, C1157) as described previously (Mohrin et al., 2010) and used in T cell suppression assays. CFSE-labeled T cells were either plated alone (10,000 T cells) or together with HSCs (5,000 T cells and 5,000 HSCs) per well of a 384-well plates in 20 mL of IMDM supplemented with 5% FBS (Corning), 50 U/ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamine, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 50 mM 2-mercaptoethanol, SCF (25 ng/ml), TPO (25 ng/ml), Flt3-L (25 ng/ml), IL-11 (25 ng/ml), IL-3 (10 ng/ml), GM-CSF (10 ng/ml), EPO (4 U/ml) and IL-2 (100 U/ml, PeproTech). TNF-a was then added together with PD-1 blocking antibody (BioLegend, 114107) or isotype IgG control (BioLegend, 400621) , both used at 20 mg/ml. Antibodies were replenished every day and co-cultures were performed for 3 days prior to CFSE analyses.
Immunofluorescence staining Cells (500-2,000 cells per slide) were pipetted onto poly-L-lysine coated sides (Sigma-Aldrich, P0425-72EA), incubated at 4 C for 30 min, fixed with 4% PFA for 10 min at room temperature, permeabilized in 0.3% Triton X-100/PBS for 2 min at room temperature and blocked in 1% BSA/PBS for 1 hour at room temperature. Slides were then incubated overnight at 4 C with either rabbit anti-p65 (Cell Signaling, 8242) or rabbit anti-p50 (Cell Signaling, 13586). Slides were washed 3 times in PBS and incubated for 1 hour at room temperature in 1% BSA/PBS with A594-conjugated goat anti-rabbit IgG (Invitrogen, A11037). Slides were then washed 3 times in PBS, incubated with 1 mg/ml DAPI/PBS for 5 min and washed twice in PBS. Slides were finally mounted using VectaShield (Vector Laboratories, H-1000) or ProLong Diamond (Invitrogen, P36961). Cells were imaged on a SP5 Upright Confocal Microscope (Leica, with 63 3 objective) or an Eclipse Ti inverted microscope (Nikon, with 60 3 objective) and images were processed using Fiji or Photoshop CC (Adobe). For quantification, fifty to 100 cells per condition were randomly captured and nuclear p65 was scored by eye or quantified with Fiji using integrated density in the nucleus.
Gene expression analyses
For RNA-sequencing analyses, RNA was purified from 10,000 HSCs and GMPs isolated from ± TNF-a-injected mice or cultured ± TNF-a using RNeasy Plus Micro Kit (QIAGEN, 74034). RNA integrity number (RIN) was determined by Bioanalyzer (Agilent Technologies) and RNA samples with RIN > 8.0 were subjected to further processing. Double-stranded cDNA was generated using Ovation RNA-Seq System V2 (Nugen, 7102), and sequencing libraries were prepared using LTP Library Preparation Kit (Kapa Biosystems, KR0453). Different adaptors were used for multiplexing samples in one lane, and pooled libraries were sequenced on Illumina HiSeq 3000 with 50 bp single end read length. Data quality was verified on Sequencing Analysis Viewer (Illumina) and demultiplexing was performed with CASAVA 1.8.2 (Illumina). Adaptor trimming, alignment, and gene-level expression quantification was performed using STAR. Principal component analysis was performed using standard packages in R, and plots were generated using the first 3 principal components. Normalization and pairwise differential expression analyses were performed in R using the DESeq2 package. For each type of TNF-a treatment, genes were regarded as highly upregulated if their expression levels were more than 3-fold elevated compared to control with false discovery rate less than 0.1. These highly upregulated genes were visualized by area-proportional Venn diagrams, and TNF-a signature genes were defined in each cell type as overlapping genes across all three TNF-a treatment. A heatmap showing fold changes for the entire TNF-a signature genes were generated with hierarchical clustering of samples with Euclidean distance. Gene Ontology (GO) analyses were performed using DAVID 6.8 on common, HSC-or GMP-specific TNF-a signature genes. Gene set enrichment analyses (GSEA) were performed using the weighted enrichment score for microarray data (GSE9476 and GSE24006) and the classic enrichment score with pre-ranked gene list according to log2 fold change for RNAseq data (GSE55689 and ours). Fluidigm gene expression analyses were done on the 96.96 Dynamic Array IFC, and analyses were performed as previously described (Hé rault et al., 2017) . In brief, 100 HSCs were directly sorted per well of a 96-well plates containing 5 ml CellsDirect lysis buffer (Invitrogen, 11753-100), reverse-transcribed and pre-amplified for 18 cycles using SuperScript III Platinum Taq Mix (Invitrogen, 12574-026) with a custom-made set of 96 proprietary target-specific primers (Fluidigm). The resulting cDNA was analyzed on a Biomark system (Fluidigm) using EvaGreen SYBR dye (Bio-Rad, 172-5211). Data were collected with Biomark Data Collection Software (Fluidigm) and analyzed using Biomark qPCR software with a quality threshold of 0.65 and linear baseline correction. Melt curves and melting temperature values for each assay reaction were checked individually, and reactions with melt curves showing multiple peaks or poor quality were discarded, leaving 87 genes excluding housekeeping genes (Actb, Gapdh, Gusb and Hprt) for further analyses. For gene expression quantification, data were exported as a Microsoft Excel .csv file and analyzed by the DDCt method using Gusb for normalization. Violin plots were generated using BoxPlotR. For quantitative RT-PCR analyses, RNA was isolated using RNeasy Plus Micro Kit, and reverse-transcribed using SuperScript III kit and random hexamers (Invitrogen, 18080-051). Runs were performed on a 7900HT Fast Real-Time PCR system or QuantStudio 7 Flex Real-Time PCR System (Applied Biosystems) using SYBR Green reagents (Kapa Biosystems, KK4603 or KK4620) and cDNA equivalent of 200 cells per reaction. Values were normalized to Actb expression levels.
Cytokine analyses
For collecting BM fluids, the four long bones (two femurs and two tibiae) of each mouse were flushed with the same 200 mL of 2% FBS/HBSS using a 0.3 mL insulin syringe with a 28G needle and spun at 500 3 g for 5 min to remove BM cells. Supernatants were further clarified by spinning down at 12,000 3 g for 10 min, and samples were subsequently stored at À80 C until use. For TNF-a measurement after TNF-a injection, 100 mL of 2 3 -diluted samples were analyzed with a mouse TNF-a ELISA Kit (eBioscience, 88-7324-22) according to the manufacturer's protocol. For cytokine measurement after pIC injection, 50 mL of 2 3 -diluted samples were analyzed with a Luminex Cytokine Mouse 20-plex panel (Thermo Scientific, LMC0006M) using a BioPlex instrument (Bio-Rad) according to the manufacturer's instructions.
QUANTITATION AND STATISTICAL ANALYSIS
All experiments were repeated as indicated; n indicates the numbers of biological replicates. Data are expressed as mean ± standard error (SEM). Mice for treatment and transplantation were randomized, samples were alternated whenever possible, and no blinding protocol was used. No statistical method was used to predetermine sample size. Pairwise statistical significance was evaluated by two-tailed Student's t test. P values < 0.05 were considered statistically significant.
DATA AND CODE AVAILABILITY
RNA-seq data used to identify TNF-a signature genes have been deposited online with the Gene Expression Omnibus (GEO) under accession number GEO: GSE115403. RNA-seq data used for GSEA analysis between mouse old versus young HSCs have been deposited to GEO under accession number GEO: GSE127522. Source Data for all the figures are provided with the paper. All other data are available from the Lead Contact upon reasonable request. Table S3 . HSC-specific TNF-α signature genes, related to Figure 4 Genes HSC fold change 
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